Skip to content

Patient experience and advocacy in ischemic heart disease

TL;DR — IHD outcomes commonly reported by trials—death, MI, revascularization—capture only part of the condition. Patients live with unpredictable angina, fatigue, breathlessness, medication burden, fear of recurrence, loss of confidence in exertion, work and sexual-role disruption, and uncertainty after a “normal” angiogram. Post-MI depression, anxiety, and post-traumatic stress are common, while kinesiophobia can prevent return to beneficial activity (Chong 2025, PMID 40142595; Bäck 2020, PMID 32886775). Placebo-controlled PCI research shows why symptoms must be measured rigorously: PCI has a true average angina effect, but individual benefit varies substantially (Rajkumar 2023, PMID 38015442; Simader 2024, PMID 38759906). Women and people with INOCA report diagnostic invalidation when non-obstructive angiography is misread as absence of disease (Grant 2024, PMID 38548464; Kunadian 2020, PMID 32626906). Advocacy priorities therefore include rapid ACS recognition, equitable diagnosis, automatic rehabilitation, affordable secondary prevention, validated patient-reported outcomes, and meaningful participation in research design.

The lived trajectory

Phase Common experiences System responsibility
Before diagnosis Intermittent symptoms, normalization, uncertainty Accessible evaluation and safety-net advice
ACS Fear, loss of control, information overload Rapid care plus clear repeated explanations
Early recovery Fatigue, medication change, fear of exertion/sex/work Rehabilitation and individualized recovery plan
Chronic angina Activity planning, symptom uncertainty, treatment trade-offs Symptom measurement and shared decisions
INOCA/MINOCA “Normal” angiogram despite symptoms/injury Mechanism-finding and diagnostic validation
Long-term prevention Pill burden, cost, adverse effects, competing illness Simplified regimens and continuity

The patient journey is not linear: recurrent symptoms can reactivate fear even without infarction, while silent disease can progress without symptom warning.

Angina as a patient-reported outcome

Angina frequency, stability, physical limitation, treatment satisfaction, and quality of life should be measured rather than inferred from stenosis. ORBITA and ORBITA-2 demonstrate both placebo/context effects and genuine PCI efficacy (Al-Lamee 2018, PMID 29103656; Rajkumar 2023, PMID 38015442).

Outcome Why it matters Measurement challenge
Symptom frequency Direct burden Recall and day-to-day variability
Physical limitation Participation in valued activity Comorbidity confounding
Nitroglycerin use Concrete rescue behavior Underuse and anticipatory avoidance
Quality of life Integrates symptom and function Generic tools may dilute angina signal
Treatment satisfaction Captures burden/preference Expectation and access influence rating

Symptoms more typical of angina predict larger placebo-controlled PCI response, but there is wide individual variability (Simader 2024, PMID 38759906).

Fear, anxiety, and depression

Post-MI psychological distress includes depression, generalized anxiety, panic-like symptom vigilance, PTSD symptoms, sleep disruption, and fear of recurrence. A recent meta-analysis found substantial prevalence of depression, anxiety, and PTSD after acute MI (Chong 2025, PMID 40142595).

The AHA scientific statement treats post-MI distress as clinically relevant to adherence, function, quality of life, and outcomes rather than an incidental reaction (Levine 2025, PMID 40977387).

Experience Potential consequence Support response
Fear of heart-rate increase Avoidance and deconditioning Supervised graded exercise and explanation
Hypervigilance to chest sensation Repeated emergency care or panic Safety plan plus psychological care
Depression/anhedonia Poor adherence and social withdrawal Screening, treatment, rehabilitation
PTSD symptoms Avoidance of hospitals/driving/activity Trauma-informed care
Partner/family fear Overprotection and role conflict Include family in education with consent

Qualitative work on kinesiophobia after MI shows that uncertainty about safe activity and bodily signals can persist despite medical clearance (Bäck 2020, PMID 32886775).

Rehabilitation access and dropout

CR improves cardiovascular mortality, hospitalization, and quality of life, yet patients are lost at referral, enrollment, attendance, and maintenance stages (Dibben 2023, PMID 36746187).

Barrier Who is disproportionately affected Design response
Travel/distance Rural patients, non-drivers Home/hybrid delivery
Work/care schedules Working-age adults, caregivers Evening/asynchronous options
Cost/insurance Low-income and underinsured groups No-cost coverage and transport support
Language/culture Minoritized and migrant communities Co-designed multilingual programs
Low perceived need Minimally symptomatic patients Automatic referral and risk explanation
Fear/comorbidity Frail, anxious, disabled patients Individualized supervised entry

Qualitative studies in India and China demonstrate that barriers are both personal and structural; transport, knowledge, physician communication, family roles, and service availability recur but their relative weight differs (Borah 2023, PMID 37033594; Xie 2022, PMID 36447215).

Diagnostic invalidation and sex/gender

Women frequently have chest pain in ACS, but differences in accompanying symptoms and clinical interpretation contribute to under-recognition (van Oosterhout 2020, PMID 32363989). Sex-specific troponin thresholds can identify myocardial injury missed by a single cutoff (Ferry 2019, PMID 31431112).

INOCA adds a second invalidation pathway: a non-obstructive angiogram may be communicated as “nothing is wrong” despite microvascular dysfunction or vasospasm (Kunadian 2020, PMID 32626906). CorMicA showed that a mechanistic diagnosis linked to therapy improves symptoms and quality of life (Ford 2018, PMID 30266608).

Medication burden and adherence

Secondary prevention can include lipid-lowering, antiplatelet, BP/heart-failure therapy, diabetes/obesity drugs, and symptom agents. Burden includes cost, refill logistics, bruising, muscle symptoms, dizziness, fatigue, injection preference, and interaction with daily roles.

SECURE showed that a polypill improved adherence and reduced MACE, establishing simplification as an outcomes intervention (Castellano 2022, PMID 36018037). Simplification must preserve contraindications and dose adjustment rather than treating every patient as identical.

Shared decision-making content

For stable revascularization, a complete discussion should state:

  1. Routine PCI does not reduce death/MI in the trial-eligible stable population (Maron 2020, PMID 32227755).
  2. PCI can improve angina, especially when symptom and lesion are concordant (Rajkumar 2023, PMID 38015442).
  3. Benefit varies; residual symptoms and repeat procedures remain possible.
  4. Medical prevention continues with or without PCI.
  5. CABG and PCI differ in recovery, stroke, MI, and repeat-revascularization profiles.

Advocacy agenda

Priority Concrete measure
ACS equity Symptom-to-first-contact and door-to-reperfusion by sex, race, geography
Rehabilitation Referral, enrollment, completion, and maintenance—not referral alone
Affordability Medication possession and cost-related nonadherence
INOCA recognition Access to validated function testing and endotype-linked care
Research participation Patient co-designed outcomes and consent materials
Mental health Screening-to-treatment completion after MI
Trial transparency Results reported in patient-meaningful absolute terms

Patient-partnered research controls

Stage Required patient contribution
Question selection Confirm outcome matters in daily life
Protocol Review burden, visit schedule and sham acceptability
Consent Test comprehension of symptom versus prognosis claims
Outcome set Include function, angina, treatment burden and uncertainty
Recruitment Identify exclusion created by travel, language or digital access
Interpretation Separate statistical from patient-important change
Dissemination Provide absolute effects and accessible negative results

Patient partnership does not replace methodological independence; it improves relevance while blinded outcome assessment, prespecification, and adverse-event reporting preserve validity.

Patient-important effects that clinical composites miss

Domain Evidence Measurement consequence
Angina frequency ORBITA found no significant between-group exercise-time gain after medication optimization, while ORBITA-2 improved a daily angina score when background antianginals were withdrawn (Al-Lamee 2018, PMID 29103656; Rajkumar 2023, PMID 38015442). Medication state, daily symptoms, unblinding, and rescue treatment must be recorded together.
Heterogeneous PCI response Baseline symptom phenotype and physiology predict part, but not all, of placebo-controlled response (Simader 2024, PMID 38759906; Foley 2025, PMID 39462291). Average benefit should not replace an individual probability distribution and uncertainty statement.
CABG versus PCI recovery FREEDOM health-status analysis found small 2-year advantages for CABG—SAQ treatment differences 1.3, 4.4, and 2.2 points across domains—with little persistent difference beyond two years (Abdallah 2013, PMID 24129463). Early recovery burden and later repeat procedures should be discussed separately from survival.
Post-MI distress Meta-analysis finds substantial depression, anxiety, and PTSD after MI (Chong 2025, PMID 40142595), and AHA synthesis treats distress as part of post-MI care (Levine 2025, PMID 40977387). Screening without a referral/treatment pathway is not an intervention.
Kinesiophobia Qualitative data show fear of movement can persist after MI and constrain return to activity (Bäck 2020, PMID 32886775). CR outcomes should include confidence, participation, and function, not exercise capacity alone.
Rehabilitation access Home-based programs can achieve broadly comparable outcomes in selected patients (McDonagh 2023, PMID 37888805), but structural barriers limit enrollment and completion (Xie 2022, PMID 36447215; Borah 2023, PMID 37033594). “Declined CR” should be decomposed into offer, affordability, transport, time, language, safety concerns, and preference.
Medication complexity A fixed-dose polypill reduced MACE after MI in SECURE and improved adherence (Castellano 2022, PMID 36018037). Simplicity may conflict with titration, contraindications, and patient attribution of adverse effects.
Diagnostic invalidation Sex/gender differences in symptoms, mechanisms, and referral contribute to delayed or dismissed diagnosis (Ferry 2019, PMID 31431112; van Oosterhout 2020, PMID 32363989; Grant 2024, PMID 38548464). Experience measures must capture uncertainty and legitimacy, not only pain intensity.

Shared decisions require option-specific numbers

For stable obstructive disease, discussion should state separately that routine PCI has not reduced death/MI in COURAGE or ISCHEMIA, that PCI can improve angina under the conditions tested in ORBITA-2, and that crossing from medical therapy to angiography remains available when symptoms are unacceptable (Boden 2007, PMID 17387127; Maron 2020, PMID 32227755; Rajkumar 2023, PMID 38015442). For ischemic LV dysfunction, the choice is not generic revascularization: CABG and PCI have different randomized evidence and recovery burdens (Velazquez 2016, PMID 27040723; Perera 2022, PMID 36027563).

A minimum decision aid should show baseline risk, absolute and relative effects with confidence intervals, time horizon, procedural burden, bleeding, likelihood of repeat procedures, expected symptom trajectory, uncertainty, and the option to revisit. It should also state whose outcomes are missing: women, advanced CKD, frail older adults, people with INOCA, and low-resource populations are often underrepresented (Bangalore 2020, PMID 32227756; Regitz-Zagrosek 2023, PMID 36316574; Kunadian 2020, PMID 32626906).

Psychological-intervention meta-analysis suggests distress outcomes can improve even when cardiovascular-event evidence remains heterogeneous (Richards 2018, PMID 29212370). That distinction supports offering care for suffering on its own merits while continuing to test whether integrated psychological and cardiac rehabilitation changes adherence, function, hospitalization, or survival.

Outcomes routinely missed by event-centered care

Clinician assessment does not reliably substitute for direct symptom measurement. In 1,257 stable-CAD outpatients, cardiologists agreed with patient-reported monthly angina only 17% of the time and classified 26% of those reporting daily/weekly angina as having none; overall agreement was moderate (κ 0.48, 95% CI 0.44–0.53) (Shafiq 2016, PMID 27179728). Routine patient-reported measures can therefore change recognition before they change treatment.

Shared decisions require correcting causal misconceptions. The PCI Choice decision aid was iteratively designed with patients and clinicians to show natural-frequency estimates for PCI plus medical therapy versus medical therapy alone, explicitly addressing beliefs that stable-disease PCI necessarily prevents death or MI; its development study established content and feasibility, not outcome effectiveness (Coylewright 2012, PMID 23226223).

Recovery extends beyond angina. Across 43 prospective studies and 34,964 patients, pooled return-to-work prevalence after coronary events was 81.1% (95% CI 75.8%–85.8%), but was lower with blue-collar versus white-collar work (65.0% vs 81.2%) and high versus low physical workload (64.1% vs 78.3%) (Kai 2022, PMID 36097026). In qualitative interviews with 17 partnered women after MI, most resumed sexual activity within four weeks, fear of triggering another MI was common, and few received clinician-initiated counseling; the small purposive sample supplies a missed-care mechanism rather than a prevalence estimate (Abramsohn 2013, PMID 23885024).

Open questions

  • Which patient-reported outcome set best captures angina, uncertainty, medication burden, and participation without excessive survey burden?
  • Can automatic home/hybrid CR enrollment reduce inequities while preserving safety? (Dibben 2023, PMID 36746187)
  • Which communication strategies reduce kinesiophobia without falsely reassuring patients about recurrent ACS? (Bäck 2020, PMID 32886775)
  • How much does a mechanistic INOCA diagnosis reduce repeated testing and diagnostic distress? (Ford 2018, PMID 30266608)
  • Do patient co-designed revascularization decisions reduce regret and improve goal-concordant care?

References

  1. Chong RJ, et al. Prevalence of Depression, Anxiety and Post-Traumatic Stress Disorder (PTSD) After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14:1786. PMID 40142595
  2. Bäck M, et al. Perceptions of Kinesiophobia in Relation to Physical Activity and Exercise After Myocardial Infarction: A Qualitative Study. Phys Ther. 2020;100:2110-2119. PMID 32886775
  3. Rajkumar CA, et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N Engl J Med. 2023;389:2319-2330. PMID 38015442
  4. Simader FA, et al. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. J Am Coll Cardiol. 2024;84:13-24. PMID 38759906
  5. Grant E, et al. Ischemic Heart Disease in Women. Med Clin North Am. 2024;108:567-579. PMID 38548464
  6. Kunadian V, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41:3504-3520. PMID 32626906
  7. Al-Lamee R, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31-40. PMID 29103656
  8. Levine GN, et al. Post-Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart Association. Circulation. 2025;152:e298-e310. PMID 40977387
  9. Dibben GO, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44:452-469. PMID 36746187
  10. Borah N, et al. Challenges to Cardiac Rehabilitation Post Coronary Artery Bypass Grafting: A Qualitative Study in Pune. Cureus. 2023;15:e35755. PMID 37033594
  11. Xie X, et al. Barriers to hospital-based phase 2 cardiac rehabilitation among patients with coronary heart disease in China: a mixed-methods study. BMC Nurs. 2022;21:333. PMID 36447215
  12. van Oosterhout REM, et al. Sex Differences in Symptom Presentation in Acute Coronary Syndromes: A Systematic Review and Meta-analysis. J Am Heart Assoc. 2020;9:e014733. PMID 32363989
  13. Ferry AV, et al. Presenting Symptoms in Men and Women Diagnosed With Myocardial Infarction Using Sex-Specific Criteria. J Am Heart Assoc. 2019;8:e012307. PMID 31431112
  14. Ford TJ, et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018;72:2841-2855. PMID 30266608
  15. Castellano JM, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387:967-977. PMID 36018037
  16. Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395-1407. PMID 32227755
  17. Foley MJ, et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Circulation. 2025;151:202-214. PMID 39462291
  18. Abdallah MS, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA. 2013;310:1581-90. PMID 24129463
  19. McDonagh ST, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2023;10:CD007130. PMID 37888805
  20. Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. PMID 17387127
  21. Velazquez EJ, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374:1511-20. PMID 27040723
  22. Perera D, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022;387:1351-1360. PMID 36027563
  23. Bangalore S, et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020;382:1608-1618. PMID 32227756
  24. Regitz-Zagrosek V, et al. Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes. Nat Rev Cardiol. 2023;20:236-247. PMID 36316574
  25. Richards SH, et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:247-259. PMID 29212370
  26. Shafiq A, et al. Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the APPEAR study. Am Heart J. 2016;175:94-100. PMID 27179728
  27. Coylewright M, et al. Shared decision making in patients with stable coronary artery disease: PCI Choice. PLoS One. 2012;7:e49827. PMID 23226223
  28. Kai SHY, et al. Prevalence and determinants of return to work after various coronary events: meta-analysis of prospective studies. Sci Rep. 2022;12:15348. PMID 36097026
  29. Abramsohn EM, et al. “I'm not just a heart, I'm a whole person here”: a qualitative study to improve sexual outcomes in women with myocardial infarction. J Am Heart Assoc. 2013;2:e000199. PMID 23885024